Remote Ischemic Conditioning in Patients Undergoing Primary Percutaneous Coronary Intervention

NCT ID: NCT07272408

Last Updated: 2025-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-01

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to detect the effects of remote ischemic conditioning on infarct size, global contractility, morbidity, mortality, and renal function in patients undergoing primary percutaneous coronary intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Myocardial infarction (MI) generally refers to segmental (regional) myocardial necrosis, typically endocardial in location, secondary to occlusion of an epicardial artery.

Primary percutaneous coronary intervention (PPCI) is a reperfusion therapy that is carried out in patients who usually have ST-segment elevation MI (STEMI) within a specific time window.

During ischemia, metabolic acidosis occurs due to anaerobic metabolism, and ischemic injury ensues. After restoration of blood supply, reactive oxygen species (ROS) production and local inflammation increase secondary injury.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Remote Ischemic Conditioning Primary Percutaneous Coronary Intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Remote ischemic conditioning

Remote ischemic conditioning (RIC) was applied to those patients.

Group Type EXPERIMENTAL

Remote ischemic conditioning

Intervention Type PROCEDURE

Remote ischemic conditioning (RIC) was applied to those patients.

Normal primary percutaneous coronary intervention

Patients followed the standard primary percutaneous coronary intervention pathway.

Group Type ACTIVE_COMPARATOR

Normal primary percutaneous coronary intervention

Intervention Type PROCEDURE

Patients followed the standard primary percutaneous coronary intervention pathway.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remote ischemic conditioning

Remote ischemic conditioning (RIC) was applied to those patients.

Intervention Type PROCEDURE

Normal primary percutaneous coronary intervention

Patients followed the standard primary percutaneous coronary intervention pathway.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age more than 18 and less than 75 years old.
* Both sexes.
* Patients with new ST-segment elevation at the J-point in V1:V6 leads with the cut-point: ≥ 1mm other than leads V2-V3 where the following cut-points apply: ≥ 2mm in men ≥ 40 years; ≥ 2.5mm in men \< 40 years, or ≥ 1.5mm in women regardless of age.
* Patients with new left bundle branch block (LBBB).

Exclusion Criteria

* ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock.
* Severe comorbidities (uncontrolled hypertension, morbid obesity, recent cerebrovascular stroke, respiratory failure, sepsis, and stage 4 \& 5 malignancy).
* End-stage renal disease on hemodialysis.
* Previous coronary artery bypass graft surgery (CABG).
* Myocardial infarct within the previous 30 days.
* Multi-vessel coronary artery disease.
* Failure of culprit vessel recanalization.
* Conditions precluding use of remote conditioning ie: paresis of upper limb.
* Life expectancy of less than 1 year due to a non-cardiac pathology.
* Patients who receive nephrotoxic drugs such as non-steroidal anti-inflammatory drugs and aminoglycosides.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Helwan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Yousry Mousa

Resident of Cardiology, Helwan University, Helwan, Egypt

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Helwan University

Helwan, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

40-2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.